Biomaterial Database

Bromocriptine is ineffective in the treatment of chronic nonfluent aphasia. 1995

A Ozeren, and Y Sarica, and H Mavi, and M Demirkiran

Department of Neurology, School of Medicine, Cukurova University, Balcali, Adana, Turkey.

The effect of bromocriptine on chronic nonfluent aphasia was investigated in 4 patients suffering from a stroke 24 to 35 months before the onset of this study (average 29 months). Two patients had Broca, one had global and the other transcortical motor aphasia. CT-scans demonstrated anterior-posterior infarctions in 3 patients and anterior infarction in one. Bromocriptine was given initially at a dosage of 10 mg/day, and of 25 mg/day during the follow ups. By means of aphasia tests, bromocriptine was found to be ineffective for the treatment of any symptoms of chronic nonfluent aphasia.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D001971	Bromocriptine	A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.	2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults
D000978	Antiparkinson Agents	Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.	Antiparkinson Drugs,Antiparkinsonian Agents,Antiparkinsonians,Agents, Antiparkinson,Agents, Antiparkinsonian,Drugs, Antiparkinson
D001039	Aphasia, Broca	An aphasia characterized by impairment of expressive LANGUAGE (speech, writing, signs) and relative preservation of receptive language abilities (i.e., comprehension). This condition is caused by lesions of the motor association cortex in the FRONTAL LOBE (BROCA AREA and adjacent cortical and white matter regions).	Agrammatism,Aphasia, Motor,Aphasia, Nonfluent,Broca Aphasia,Dysphasia, Broca,Agrammatic Broca Aphasia,Agrammatic Broca's Aphasia,Aphasia, Anterior,Aphasia, Ataxic,Aphasia, Expressive,Aphasia, Frontocortical,Dysphasia, Broca's,Verbal Aphasia Syndrome,Agrammatic Broca Aphasias,Agrammatic Broca's Aphasias,Agrammatic Brocas Aphasia,Anterior Aphasia,Anterior Aphasias,Aphasia Syndrome, Verbal,Aphasia Syndromes, Verbal,Aphasia, Agrammatic Broca,Aphasia, Agrammatic Broca's,Aphasias, Agrammatic Broca,Aphasias, Agrammatic Broca's,Aphasias, Anterior,Aphasias, Ataxic,Aphasias, Broca,Aphasias, Frontocortical,Ataxic Aphasia,Ataxic Aphasias,Broca Aphasia, Agrammatic,Broca Aphasias,Broca Aphasias, Agrammatic,Broca Dysphasia,Broca's Aphasia, Agrammatic,Broca's Aphasias, Agrammatic,Broca's Dysphasia,Dysphasia, Brocas,Expressive Aphasia,Frontocortical Aphasia,Frontocortical Aphasias,Motor Aphasia,Nonfluent Aphasia,Syndrome, Verbal Aphasia,Syndromes, Verbal Aphasia,Verbal Aphasia Syndromes
D017211	Treatment Failure	A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series.	Failure, Treatment,Failures, Treatment,Treatment Failures